arrow
P

Philippe Conus

king's college london
H指数:64
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Unraveling Suicidal Ideation and Behaviors in a Global Cohort of Individuals at Clinical High-Risk for Psychosis: Multivariable Correlates and Subthreshold Psychotic Symptoms

揭示全球临床高风险精神分裂症个体中的自杀意念与行为:多变量相关因素和阈下精神病症状

2026-09-130
OAAI
Processing Speed and Verbal Learning Ability as Predictors of Assessor-Rated and Ecological Momentary Assessment Self-Reported Functioning: Findings from AMP SCZ

处理速度和言语学习能力作为评估者评定和生态瞬时评估自报功能表现的预测因素:AMP SCZ的研究发现

2026-08-030
PRE
The Long-Term Follow-Up TIPP Project: LOFT Study Protocol, a 20-Year Prospective Study of Early Psychosis Patients

长期随访TIPP项目:LOFT研究方案,一项对早期精神病患者进行的20年前瞻性研究

2026-01-010
OAAI
Mental health, coping and related risk factors during the first 2 years of the COVID-19 pandemic in children: Nationally representative, multi-wave, cross-sectional results from 12 countries from the global COH-FIT study

儿童在COVID-19大流行前2年的心理健康、应对方式及相关风险因素:全球COH-FIT研究来自12个国家的全国代表性、多波次、横断面研究结果

2025-12-180
OAAI
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative

收集语言、语音声学和面部表情数据以预测精神分裂症及其他临床结果:AMP® SCZ倡议的策略

2025-10-150
OAAI
Dietary caffeine to assess CYP1A2 activity, tailor clozapine doses, and predict treatment response: genetic, epigenetic and clinical analyses

膳食咖啡因用于评估CYP1A2活性、调整氯氮平剂量及预测治疗反应:遗传学、表观遗传学和临床分析

2025-09-170
OAAI
CYP2D6 Genotypes Do Not Affect Clozapine Levels in a Large, Multicenter Cohort: Time Has Come to Revise Food and Drug Administration's Clozapine Packet Insert

CYP2D6基因型不影响大型多中心队列中氯氮平的血药浓度:是时候修订美国食品药品监督管理局(FDA)的氯氮平药品说明书了。

2025-09-010
OAAI
Influence of CYP2D6 Genotypes and Phenotypes on the Plasma Levels and Clinical Response to Aripiprazole

CYP2D6基因型和表型对阿立哌唑血浆水平及临床反应的影响

2025-07-010
OAAI
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures

加速药品合作计划®精神分裂症项目中的脑电图协议:测量指标的可靠性与稳定性

2025-06-060
OAAI
Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program

加速药物合作®精神分裂症计划中的数字健康技术

2025-06-030
OAAI
Pathways between childhood trauma, clinical symptoms, and functioning in new-onset psychosis: novel insights from a network analysis approach

儿童创伤、临床症状与新发精神病之间的影响路径:来自网络分析方法的全新见解

2025-05-150
OA
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample

加速药物伙伴关系中的认知评估®精神分裂症计划: 在不同的国际样本中协调优先事项和策略

2025-03-240
OAAI